System Design – Proposed Mechanism of Action for LUMISIGHT™*: Investigational Optical Imaging Agent

 

LUMISIGHT Optical Imaging Agent is an investigational fluorescent molecule that is optically inactive when injected in the patient and activated by the enzymatic activity in and around the tumor. LUMISIGHT leverages the host-immune response common to all solid tumors, rather than targeting certain receptors of a specific type of cancer.

 

LUMISIGHT Optical Imaging Agent: Tumor-Type Agnostic

LUMISIGHT is activated by the physiology of the tumor and its invasive front – the area at the edge of the tumor that includes cancer cells and a halo of host-response immune cells.

 

LUMISIGHT, A PROTEASE-ACTIVATED MOLECULE
is injected intravenously into the patient ~2-6 hours before surgery

 

THE TUMOR MICROENVIRONMENT
is the area where LUMISIGHT naturally
permeates to produce an immuno- and
tumor-activated fluorescent signal

 

THE INVASIVE FRONT
is the area within the tumor microenvironment where cancer cells interact with cancer-associated immune cells such as macrophages and secrete more of the proteases that LUMISIGHT is designed to activate

 

HAND-HELD IMAGING PROBE
enables surgeon to scan, inside the breast cavity, for residual cancer, activated and illuminated by LUMISIGHT

 

*CAUTION: LUMISIGHT and Lumicell Direct Visualization System (DVS) are investigational products that are limited by Federal (or United States) law to investigational use. LUMISIGHT and Lumicell DVS are not authorized for marketing for any indication in any jurisdiction.